Psychiatry & Neurology, Clinical Neurophysiology · Washington, DC
NPI
1104876713
Since 2006
Specialty
Psychiatry & Neurology, Clinical Neurophysiology
Code 2084N0600X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
110 Irving St NW, #2a38
Washington, DC, 20010
Phone (202) 877-0333
Groups this clinician bills Medicare through
Medicare paid, 2024
$99K
930 services
Medicare patients, 2024
500
Average age 72
Drug cost, 2024
$242K
855 prescriptions
Company payments, 2024
$14.28
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Lin was code 99215 (office e&m - established), 201 times for 140 patients. In total Mark Lin billed 930 services in 27 codes, and Medicare paid $99K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-01-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 201 | 140 | $153.73 | $31K |
| 99232 Hospital E&M - Subsequent | Facility | 108 | 72 | $70.47 | $7,611 |
| 99214 Office E&M - Established | Office | 96 | 82 | $98.55 | $9,461 |
| 99214 Office E&M - Established | Facility | 72 | 65 | $82.37 | $5,931 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 66 | 61 | $15.00 | $990 |
| 99222 Hospital E&M - Initial | Facility | 61 | 60 | $114.09 | $6,960 |
| 99205 Office E&M - New | Office | 54 | 54 | $189.20 | $10K |
| 99233 Hospital E&M - Subsequent | Facility | 52 | 30 | $106.86 | $5,557 |
| 99204 Office E&M - New | Facility | 43 | 43 | $115.40 | $4,962 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 35 | 27 | $28.51 | $998 |
| 99204 Office E&M - New | Office | 31 | 31 | $141.78 | $4,395 |
| 99223 Hospital E&M - Initial | Facility | 27 | 27 | $154.29 | $4,166 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 19 | 19 | $15.23 | $289 |
| 99215 Office E&M - Established | Facility | 13 | 13 | $125.46 | $1,631 |
| 99205 Office E&M - New | Facility | 12 | 12 | $168.29 | $2,019 |
By year: 2022 $101K for 922 services; 2023 $85K for 793 services; 2024 $99K for 930 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark Lin prescribed most often to Medicare patients was Carbidopa-Levodopa-Entacapone (Carbidopa/Levodopa/Entacapone), with 241 prescriptions and refills. In total Mark Lin wrote 855 Medicare prescriptions that cost $242K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 241 | 472 | 52 | $113K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 109 | 225 | 36 | $2,018 |
| Gabapentin Generic | 56 | 72 | 17 | $739 |
| Levetiracetam Generic | 47 | 83 | Under 11 | $1,139 |
| Primidone Generic | 42 | 68 | Under 11 | $917 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 40 | 66 | 15 | $1,636 |
| Donepezil Hcl Generic | 30 | 68 | 11 | $485 |
| Propranolol Hcl Er Propranolol Hcl | 29 | 55 | Under 11 | $1,300 |
| Topiramate Generic | 28 | 40 | Under 11 | $385 |
| Levetiracetam Er Levetiracetam | 27 | 45 | Under 11 | $2,550 |
| Clonazepam Generic | 22 | 22 | Under 11 | $348 |
| Amitriptyline Hcl Generic | 14 | 18 | Under 11 | $93.83 |
| Lacosamide Generic | 14 | 24 | Under 11 | $2,034 |
| Rytary Carbidopa/Levodopa | 14 | 14 | Under 11 | $11K |
| Tetrabenazine Generic | 12 | 12 | Under 11 | $23K |
Brand drugs: - claims; generic drugs: 683 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Mark Lin $14.28 ($14.28 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $14.28.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $14.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.